Key Spec Table
|Species Reactivity||Key Applications||Host||Format||Antibody Type|
|H, Vrt||WB, IP, DB, ICC, ELISA, Mplex, ChIP||M||Purified||Monoclonal Antibody|
|Presentation||Purified mouse monoclonal IgG1κ in PBS with 0.05% sodium azide.|
|Safety Information according to GHS|
|Material Size||100 µg|
|Reference overview||Pub Med ID|
|Embryonic MicroRNA-369 Controls Metabolic Splicing Factors and Urges Cellular Reprograming.|
Konno, M; Koseki, J; Kawamoto, K; Nishida, N; Matsui, H; Dewi, DL; Ozaki, M; Noguchi, Y; Mimori, K; Gotoh, N; Tanuma, N; Shima, H; Doki, Y; Mori, M; Ishii, H
PloS one 10 e0132789 2015
Noncoding microRNAs inhibit translation and lower the transcript stability of coding mRNA, however miR-369 s, in aberrant silencing genomic regions, stabilizes target proteins under cellular stress. We found that in vitro differentiation of embryonic stem cells led to chromatin methylation of histone H3K4 at the miR-369 region on chromosome 12qF in mice, which is expressed in embryonic cells and is critical for pluripotency. Proteomic analyses revealed that miR-369 stabilized translation of pyruvate kinase (Pkm2) splicing factors such as HNRNPA2B1. Overexpression of miR-369 stimulated Pkm2 splicing and enhanced induction of cellular reprogramming by induced pluripotent stem cell factors, whereas miR-369 knockdown resulted in suppression. Furthermore, immunoprecipitation analysis showed that the Argonaute complex contained the fragile X mental retardation-related protein 1 and HNRNPA2B1 in a miR-369-depedent manner. Our findings demonstrate a unique role of the embryonic miR-369-HNRNPA2B1 axis in controlling metabolic enzyme function, and suggest a novel pathway linking epigenetic, transcriptional, and metabolic control in cell reprogramming.
|Decreased histone H2B monoubiquitination in malignant gastric carcinoma.|
Wang, ZJ; Yang, JL; Wang, YP; Lou, JY; Chen, J; Liu, C; Guo, LD
World journal of gastroenterology 19 8099-107 2013
To investigate H2B monoubiquitination (uH2B) and H3K4 di- and tri-methylation (H3K4-2me, H3K4-3me) levels and their clinical significance in gastric cancer (GC).Immunohistochemistry (IGC) was used to detect the differential levels of uH2B, H3K4-2me and H3K4-3me modifications in GC specimens from chemo/radiotherapy-naïve patients who underwent potentially curative surgical resection (n = 159) and in a random sampling of non-tumor gastric epithelium specimens (normal controls, n = 20). The immunohistochemistry (IHC)-detected modifications were classified as negative, low-level, or high-level using a dual-rated (staining intensity and percentage of positively-stained cells) semi-quantitative method. The relationships between uH2B modification levels and clinicopathological parameters of GC were assessed by a Wilcoxon rank sum test (pairwise comparisons) and the Kruskal-Wallis H test (multiple comparisons). The correlation between uH2B modification and survival was estimated by Kaplan-Meier analysis, and the role of uH2B as an independent prognostic factor for survival was assessed by multivariate Cox regression analysis.The presence and level of H3K4-2me and H3K4-3me IHC staining was similar between the normal controls and GC specimens. In contrast, the level of uH2B was significantly lower in the malignant gastric tissues (vs normal control tissues) and decreased along with increases in dedifferentiation (well differentiated greater than moderately differentiated greater than poorly differentiated). The level of uH2B correlated with tumor differentiation (P less than 0.001), Lauren's diffuse- and intestinal-type classification (P less than 0.001), lymph node metastasis (P = 0.049) and tumor-node-metastasis stage (P = 0.005). Patients with uH2B+ staining had higher 5-year survival rates than patients with uH2B-staining (52.692 ± 2.452 vs 23.739 ± 5.207, P less than 0.001). The uH2B level was an independent prognostic factor for cancer-specific survival (95%CI: 0.237-0.677, P = 0.001).uH2B displays differential IHC staining patterns corresponding to progressive stages of GC. uH2B may contribute to tumorigenesis and could be a potential therapeutic target.
|The G2/M regulator histone demethylase PHF8 is targeted for degradation by the anaphase-promoting complex containing CDC20.|
Lim, HJ; Dimova, NV; Tan, MK; Sigoillot, FD; King, RW; Shi, Y
Molecular and cellular biology 33 4166-80 2013
Monomethylated histone H4 lysine 20 (H4K20me1) is tightly regulated during the cell cycle. The H4K20me1 demethylase PHF8 transcriptionally regulates many cell cycle genes and is therefore predicted to play key roles in the cell cycle. Here, we show that PHF8 protein levels are the highest during G2 phase and mitosis, and we found PHF8 protein stability to be regulated by the ubiquitin-proteasome system. Purification of the PHF8 complex led to the identification of many subunits of the anaphase-promoting complex (APC) associated with PHF8. We showed that PHF8 interacts with the CDC20-containing APC (APC(cdc20)) primarily during mitosis. In addition, we defined a novel, KEN- and D-box-independent, LXPKXLF motif on PHF8 that is required for binding to CDC20. Through various in vivo and in vitro assays, we demonstrate that mutations of the LXPKXLF motif abrogate polyubiquitylation of PHF8 by the APC. APC substrates are typically cell cycle regulators, and consistent with this, the loss of PHF8 leads to prolonged G2 phase and defective mitosis. Furthermore, we provide evidence that PHF8 plays an important role in transcriptional activation of key G2/M genes during G2 phase. Taken together, these findings suggest that PHF8 is regulated by APC(cdc20) and plays an important role in the G2/M transition.
|LINT, a novel dL(3)mbt-containing complex, represses malignant brain tumour signature genes.|
Meier, K; Mathieu, EL; Finkernagel, F; Reuter, LM; Scharfe, M; Doehlemann, G; Jarek, M; Brehm, A
PLoS genetics 8 e1002676 2012
Mutations in the l(3)mbt tumour suppressor result in overproliferation of Drosophila larval brains. Recently, the derepression of different gene classes in l(3)mbt mutants was shown to be causal for transformation. However, the molecular mechanisms of dL(3)mbt-mediated gene repression are not understood. Here, we identify LINT, the major dL(3)mbt complex of Drosophila. LINT has three core subunits-dL(3)mbt, dCoREST, and dLint-1-and is expressed in cell lines, embryos, and larval brain. Using genome-wide ChIP-Seq analysis, we show that dLint-1 binds close to the TSS of tumour-relevant target genes. Depletion of the LINT core subunits results in derepression of these genes. By contrast, histone deacetylase, histone methylase, and histone demethylase activities are not required to maintain repression. Our results support a direct role of LINT in the repression of brain tumour-relevant target genes by restricting promoter access.
|Differential H3K4 methylation identifies developmentally poised hematopoietic genes.|
Orford, Keith, et al.
Dev. Cell, 14: 798-809 (2008) 2008
|Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes.|
Huang, Yi, et al.
Proc. Natl. Acad. Sci. U.S.A., 104: 8023-8 (2007) 2007
|DNA methylation dictates histone H3K4 methylation.|
Okitsu, Cindy Yen and Hsieh, Chih-Lin
Mol. Cell. Biol., 27: 2746-57 (2007) 2007
|Anti-Dimethyl Histone H3 (Lys4) Antibody, clone CMA303, 05-1338 ChIP-seq Analysis|
|Anti-dimethyl-Histone H3 (Lys4) ChIP-seq Analysis|